Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2020

Open Access 01-12-2020 | Acute Myeloid Leukemia | Review

VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy

Authors: Xing Huang, Xiaozhen Zhang, Enliang Li, Gang Zhang, Xun Wang, Tianyu Tang, Xueli Bai, Tingbo Liang

Published in: Journal of Hematology & Oncology | Issue 1/2020

Login to get access

Abstract

VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer immunity than previously recognized. Here, we review the current knowledge on the therapeutic phenotypes and molecular mechanisms that underlie the contradictory roles of VISTA in checking anti-cancer immune responses. Furthermore, we highlight the potential indeterminacy of VISTA-targeted strategies in cancer immunotherapy, with in silico analyses. In fact, VISTA functions like a homeostatic regulator that actively normalizes immune responses. Thus, the regulatory role of VISTA in anti-cancer immunity remains to be fully elucidated.
Literature
1.
Couzin-Frankel J. CanceriImmunotherapy. Science. 2013;342(6165):1432–3.PubMed
2.
3.
Tang J, et al. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 2018;17(12):854–5.PubMed
4.
Wang L, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011;208(3):577–92.PubMedPubMedCentral
5.
Borggrewe M, et al. VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases. Glia. 2018;66(12):2645–58.PubMedPubMedCentral
6.
ElTanbouly MA, et al. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity. Semin Immunol. 2019;42:101308.PubMedPubMedCentral
7.
Flies DB, et al. Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol. 2011;187(4):1537–41.PubMedPubMedCentral
8.
9.
Yoon KW, et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science. 2015;349(6247):1261669.PubMedPubMedCentral
10.
Bharaj P, et al. Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals. PLoS One. 2014;9(10):e109103.PubMedPubMedCentral
11.
Flies DB, Higuchi T, Chen L. Mechanistic assessment of PD-1H coinhibitory receptor-induced T cell tolerance to allogeneic antigens. J Immunol. 2015;194(11):5294–304.PubMedPubMedCentral
12.
Flies DB, et al. Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity. J Clin Invest. 2014;124(5):1966–75.PubMedPubMedCentral
13.
Villarroel-Espindola F, et al. Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res. 2018;24(7):1562–73.PubMed
14.
Gao J, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23(5):551–5.PubMedPubMedCentral
15.
Xie S, et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother. 2018;67(11):1685–94.PubMed
16.
ElTanbouly MA. et al. Coming of age as a multi-lineage immune checkpoint. Clin Exp Immunol: VISTA; 2020.
17.
Blando J, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019;116(5):1692–7.PubMedPubMedCentral
18.
Xu W, et al. Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression. Cancer Immunol Res. 2019;7(9):1497–510.PubMedPubMedCentral
19.
Rosenbaum, S.R., et al., FOXD3 regulates VISTA expression in melanoma. Cell Reports, 2020. 30(2): p. 510-524. e6.
20.
Kondo Y, et al. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol. 2016;57:54–60.PubMed
21.
Liu J, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci. 2015;112(21):6682–7.PubMed
22.
Kakavand H, et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol. 2017;30(12):1666–76.PubMed
23.
Xie X, et al. High-density infiltration of V-domain immunoglobulin suppressor of T-cell activation up-regulated immune cells in human pancreatic cancer. Pancreas. 2018;47(6):725–31.PubMed
24.
Byers JT, et al. Expression of the novel costimulatory molecule B7-H5 in pancreatic cancer. Ann Surg Oncol. 2015;22(3):1574–9.
25.
Ni L, Dong C. New checkpoints in cancer immunotherapy. Immunol Rev. 2017;276(1):52–65.PubMed
26.
Hong S, et al. Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy. Protein Cell. 2019;10(11):840–5.PubMedPubMedCentral
27.
Hernandez-Martinez J-M, et al. VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy. J Thoracic Dis. 2018;10(12):6378–82.
28.
Brcic L, et al. Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung. Virchows Arch. 2018;472(4):589–98.PubMedPubMedCentral
29.
Kim TK, et al. Pd-1 h (vista) induces immune evasion in acute myeloid leukemia. Blood. 2017;130(Supplement 1):2658.
30.
Wang L, et al. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. OncoImmunology. 2018;7(9):e1469594.PubMedPubMedCentral
31.
32.
Vesely M, Gaule P, Chen L. 843 immune checkpoint molecule PD-1H/VISTA expression correlates with melanoma survival. J Investig Dermatol. 2019;139(5):S145.
33.
Kuklinski LF, et al. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunol Immunother. 2018;67(7):1113–21.PubMed
34.
Jindal V. Immunotherapy: a glimmer of hope for metastatic prostate cancer. Chin Clin Oncol. 2018;7:61.PubMed
35.
Lamble, A., et al., Enhanced VISTA expression in a subset of patients with acute myeloid leukemia. 2016, American Society of Hematology Washington, DC.
36.
Zaravinos A, et al. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. J Exp Clin Cancer Res. 2019;38(1):1–18.
37.
Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225–39.PubMed
38.
Hasmim M, et al. Cutting edge: hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-β1. J Immunol. 2013;191(12):5802–6.PubMed
39.
Chen, H., et al. Different clinical significance of novel B7 family checkpoints, VISTA and HHLA2, in human lung adenocarcinoma and colorectal cancer. in LABORATORY INVESTIGATION. 2019. NATURE PUBLISHING GROUP 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA.
40.
Liao H, et al. Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer. Oncol Lett. 2018;16(3):3465–72.PubMedPubMedCentral
41.
Zong L, et al. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. Cancer Immunol Immunother. 2019;69(1):33–42.PubMedPubMedCentral
42.
Lines JL, et al. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res. 2014;2(6):510–7.PubMedPubMedCentral
43.
Le Mercier I, et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 2014;74(7):1933–44.PubMed
44.
Ru B, et al. TISIDB: an integrated repository portal for tumor–immune system interactions. Bioinformatics. 2019;35(20):4200–2.PubMed
45.
Böger C, et al. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: a future perspective for a combined gastric cancer therapy? OncoImmunology. 2017;6(4):e1293215.PubMedPubMedCentral
46.
Loeser H, et al. The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma. Oncoimmunology. 2019;8(5):e1581546.PubMedPubMedCentral
47.
Zhang M, et al. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer. 2018;18(1):511.PubMedPubMedCentral
48.
49.
Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530.PubMed
50.
Roychowdhury S, Chinnaiyan AM. Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin. 2016;66(1):75–88.PubMed
51.
Tang Z, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.PubMedPubMedCentral
52.
Tang Z, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–60.PubMedPubMedCentral
53.
Gou R, et al. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins. J Transl Med. 2019;17(1):275.PubMedPubMedCentral
Metadata
Title
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
Authors
Xing Huang
Xiaozhen Zhang
Enliang Li
Gang Zhang
Xun Wang
Tianyu Tang
Xueli Bai
Tingbo Liang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2020
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-020-00917-y

Other articles of this Issue 1/2020

Journal of Hematology & Oncology 1/2020 Go to the issue

Research

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study

Rapid communication

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia

Review

Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer

Review

Emerging therapies in mantle cell lymphoma

Correction

Correction to: The design and development of covalent protein-protein interaction inhibitors for cancer treatment

Research

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits